Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience, Inc. is a global bioscience company headquartered in Los Angeles, California, whose common stock trades on the Nasdaq under the ticker NAGE. The company was formerly known as ChromaDex Corp. and took its current name in 2025 to align with its core ingredient brand.

The company focuses on healthy aging research centered on nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production. Its patented ingredient Niagen is a form of nicotinamide riboside, a precursor to NAD+. The company sells Niagen directly to consumers through its Tru Niagen dietary supplement brand, supplies the ingredient to other consumer product companies, and has introduced pharmaceutical-grade Niagen for intravenous and injectable use in clinics.

Niagen Bioscience supports clinical research on NAD+ biology through partnerships with universities and research institutions, and it also operates an analytical reference standards business serving the food, supplement and pharmaceutical industries.